What is the Difference Between BRCA1 and BRCA2 Mutations?

While both BRCA1 and BRCA2 mutations significantly increase the lifetime risk for breast and ovarian cancers, the exact percentages, age of onset, and associated cancer types differ between the two genes ^[1][2]. In general, BRCA1 mutations are linked to earlier breast cancer onset, a much higher risk of ovarian cancer, and triple-negative breast cancer ^[2][3]. In contrast, BRCA2 mutations present slightly later breast cancer risks and are more strongly associated with male breast cancer, aggressive prostate cancer, pancreatic cancer, and melanoma ^[2][4][5].

Breast Cancer: Risk and Subtypes

For women, the overall lifetime risk of developing breast cancer by age 80 is similarly high for both genes, but the timing differs ^[2].

• Lifetime Risk: The cumulative risk by age 80 is approximately 72% for BRCA1 carriers and 69% for BRCA2 carriers ^[2].
• Age of Onset: Breast cancer incidence rises rapidly between ages 30 and 40 for BRCA1 carriers, whereas it peaks later, between ages 40 and 50, for BRCA2 carriers ^[2].
• Contralateral Breast Cancer: The 20-year risk of developing a second cancer in the opposite breast (after a first diagnosis) is 40% for BRCA1 compared to 26% for BRCA2 ^[2].
• Triple-Negative Breast Cancer (TNBC): BRCA1 mutations are strongly linked to this aggressive breast cancer subtype, which lacks estrogen, progesterone, and HER2 receptors ^[3]. A large majority of breast cancers that develop in BRCA1 carriers are TNBC. Among all women diagnosed with TNBC in the general population, roughly 10% to 20% harbor a BRCA mutation, though some specific high-risk groups have shown rates up to 45% ^[6].

Ovarian Cancer: Risk and Timing

The difference in ovarian cancer risk is one of the most significant distinctions between the two genes ^[2].

• Lifetime Risk: By age 80, the lifetime risk of ovarian cancer is roughly 44% for BRCA1 mutations, compared to 17% for BRCA2 mutations ^[2].
• Preventive Guidelines: Because of the earlier onset in BRCA1, clinical guidelines typically recommend a prophylactic salpingo-oophorectomy (a risk-reducing surgery to remove the ovaries and fallopian tubes) between ages 35 and 40 for BRCA1 carriers ^[7][8]. For BRCA2 carriers, this surgery is generally recommended slightly later, between ages 40 and 45 ^[7][8].

While this surgery is highly effective at preventing cancer, it also causes immediate surgical menopause and the loss of natural fertility. Doctors will work closely with you to time this procedure around your family planning goals and discuss options for fertility preservation and managing early menopause.

Risks for Men: Breast and Prostate Cancer

Both genes can impact men, but BRCA2 carries significantly higher risks for specific male-dominated cancers ^[4].

• Male Breast Cancer: BRCA2 mutations carry a much higher penetrance (the likelihood of the disease occurring in someone with the gene) for male breast cancer than BRCA1 ^[4]. For context, the lifetime risk of male breast cancer for a BRCA2 carrier is roughly 1% to 8%, compared to less than 0.1% in the general population.
• Prostate Cancer: Men with a BRCA2 mutation face an increased risk of developing prostate cancer. Importantly, the disease is often more aggressive and associated with poorer survival outcomes compared to the general population ^[4][9]. Because of this elevated risk for an aggressive disease, doctors often recommend specialized or earlier screening (such as PSA testing) for BRCA2 carriers to catch any cancer as early as possible.

Other Cancers: Pancreatic and Melanoma

BRCA2 mutations are also more closely tied to other cancers outside the breast and reproductive systems.

• Pancreatic Cancer: BRCA2 carriers have a significantly higher relative risk (up to a 21-fold increase) of developing pancreatic cancer compared to the general population ^[4][5]. However, because the general population risk is very low (around 1.5%), the absolute lifetime risk remains relatively low (often estimated around 5% to 10%) ^[5]. BRCA1 mutations show a much lower, less significant association.
• Melanoma: Research has shown a trend toward an increased risk of melanoma (skin cancer) for BRCA2 carriers, whereas BRCA1 carriers generally do not show a statistically significant increase ^[5].

Targeted Treatments

Beyond prevention, knowing which specific gene is mutated can also offer hope and guide treatment if cancer does occur. For example, targeted therapies like PARP inhibitors (such as olaparib) have shown great effectiveness in treating cancers associated with BRCA1 and BRCA2 mutations, including aggressive prostate cancer ^[10]. Similarly, BRCA1 carriers with TNBC often have higher rates of success (pathological complete response) when treated with specific chemotherapy regimens, such as platinum-containing drugs ^[11].

Summary Comparison Table

To help visualize these differences, here is a quick summary of the average lifetime risks and guidelines for each gene ^[2][4][7]:

Personalizing Your Risk

It is important to remember that these percentages represent averages across large groups of people. Your exact, individual risk can be higher or lower depending on your personal family history (such as the number of first- and second-degree relatives diagnosed with cancer) and the specific location of the mutation within the gene ^[2].